

DANIEL P. ARRISON, M.D., F.A.C.S.

Bel Air CUA Office
4-A North Avenue, Suite 202
Bel Air, MD 21014
410-803-0089 - Office
410-803-0251 - Fax

Franklin Square / White Marsh CUA Office
6830 Hospital Drive, Suite 204
Baltimore, MD 21237
410-391-6131 - Office
410-391-6144 - Fax

Havre De Grace CUA Office
805 S. Union Avenue
Havre De Grace, MD 21078
410-942-0130 - Office
410-939-3538 - Fax

CERTIFICATION:

October 2005	Fellow in the American College of Surgeons
February 2004	American Board of Urology Part II orals Pass
June 2002	American Board of Urology Part I Pass
June 1994	National Board of Medical Examiners Part I Pass
August 1995	National Board of Medical Examiners Part II Pass

LICENSURE:

Maryland state medical license: 2002
Pennsylvania state medical license: 1998

EDUCATION:

1992-1996 M.D., Temple University
School of Medicine
Philadelphia, Pennsylvania

1987-1991 B.S., St. Joseph's University
Biology
Philadelphia, Pennsylvania

CLINICAL EXPERIENCE:

2007-Present Chesapeake Urology Research Associates

2002-Present Clinical Urologist
Chesapeake Urology Associates
Baltimore, MD

1998-2002 Urology Residency
Temple University Hospital
Department of Urology
Philadelphia, Pennsylvania

1997-1998 General Surgery Resident
Temple University Hospital
General Surgery Department
Philadelphia, Pennsylvania

1996-1997 General Surgery Intern
Temple University Hospital
General Surgery Department
Philadelphia, Pennsylvania

RESEARCH EXPERIENCE:

1987-1994 Rhone-Poulenc Rorer
Collegeville, Pennsylvania
Cardiovascular Division Summer intern and part-time positions

1/2000-6/2000 Temple University Hospital
Department of Urology

8/2007-Present Sub-Investigator, Pfizer
12-WK, Randomized, Double-Blind, Placebo controlled, Parallel
Group, Multicenter trial to Evaluate the Efficacy and Safety of a
Fesoterodine Flexible Dose regimen in Patients with Overactive
Bladder

6/2007-Present Sub-Investigator, Theralogix
A Randomized, Double-Blind, Placebo-
Controlled Trial of the Effect of a

Novel Nutritional Supplement on PSA
Kinetics in Men with Biochemical Recurrence
After Definitive therapy for Prostate Cancer.

5/2007-Present

Sub-Investigator, Boston Scientific/Celsion
A 5-Year Trial for Post-Marketing Study Using Prolieve Microwave
Therapy For The Treatment of Benign Prostatic Hyperplasia (BPH)

PROFESSIONAL ASSOCIATIONS:

1996-Present

American Urological Association

2003-Present

American Association of Clinical Urologists

2003-Present

Baltimore County Medical Association

2004-Present

Upper Chesapeake Medical Center CME committee

ABSTRACTS:

Hydrodistension increases inducible nitric oxide synthase in dog
bladder mucosa. *Society for Urodynamics & Female Urology*. June 2001.
Ruggieri Michael R., Braverman Alan S., Arrison Daniel P., Pontari
Michel A.

Intravesical BCG and Alpha 2b interferon for superficial transitional
cell carcinoma. *Mid-Atlantic Section of the AUA*. October 2001.
Arrison Daniel P., Uzzo Robert G., Greenberg Richard E.